Brain+ A/S (“Brain+”) informs that CST Assistant v2.0 has been released in Denmark. The CST Assistant is a unique software-based solution for the preparation and delivery of Cognitive Stimulation Therapy (CST) to people with dementia.

On 14 June 2024, the company informed in a news release (see : The CST Assistant v2.0 is now ready for release in Denmark and on track for release in the UK end Q3 2024) that the development of this upgraded version of the product had been completed. After a period of internal release testing, the Danish CST Assistant v2.0 has now been made commercially available for existing Brain+ customers and will in the coming months be introduced to other Danish municipality sales leads. In addition, the new product version will be used by partners in the ongoing CO-PI grant-covered project, which aims to implement and scale the use of the CST Assistant to support CST delivery to people with dementia in Denmark.

CST is the leading evidence-based non-pharmacological therapy for dementia, recommended by the World Alzheimer’s Association and the World Health Organization (WHO) for worldwide implementation. The Danish version 1.0 of the CST Assistant was made available for CST therapists for user testing and feedback in Q4 2022, which has led to 6 sales contracts with 4 municipalities. The release of version 2.0 introduces several new features and functional improvements aimed at making the preparation of CST sessions easier and faster, enhancing flexibility and fidelity in conducting the therapy, and offering an overall more personalized experience for CST therapists and people with dementia receiving CST.

Simon Nielsen, Chief Strategy & Innovation Officer in Brain+ commented on the news: "The Danish release of version 2.0 of the CST Assistant is an important milestone in our quest to provide better treatment options for people with dementia. This new version has been developed in close collaboration with CST therapists and dementia experts in both Denmark and the UK – and we have been met with solid acknowledgement for the relevance of our offering. With the Danish release of this significantly upscaled product version now complete, our focus is on getting the English version certified for planned launch of the product in the UK as medical device before the end of Q3."

The Danish market is important to Brain+ in terms of valuable user input and learnings; however, it is small and without established reimbursement options for healthtech solutions, which makes adoption relatively slow. The company’s commercial focus is therefore on the UK market, which has higher healthtech readiness with established reimbursement pathways and the highest CST penetration globally. In the UK, CST is the only non-pharmacological therapy endorsed by the National Institute for Health and Care Excellence (NICE), and the National Health Service (NHS) Memory Services are obliged to offer CST to people diagnosed with dementia as part of the UK Memory Services National Accreditation Program (MSNAP).

The CST-Assistant v2.0 will be introduced in the UK as a medical device with medical claims, facilitating better access to reimbursement pathways for medical software solutions. In Denmark, the product has been introduced as a regular health product due to lack of reimbursement options, bypassing the costs of EU medical device certification.

Contact Information

CEO and Co-founder, Kim Baden-Kristensen, + 45 31 39 33 17 (SMS), kim@brain-plus.com

OR

CFO, Hanne Vissing Leth, + 45 53 88 99 02, hanne@brain-plus.com
 

Brain+ mission: Become the preferred provider of certified healthtech solutions for better dementia management, servicing one million people affected by dementia by 2030.

.